투자판단관련주요경영사항(임상시험계획승인신청) (CLDN18.2 항체-약물 접합체 (ADC) LCB02A의 제 1/2상 임상시험의 미국 임상시험계획(IND) 승인 신청)[코]
리가켐바이오· 141080 More filings
Received: 4/14/2026 · Reporter: 리가켐바이오
A summary for this filing type is not yet available. Please refer to the original DART filing.
🏢 Past 12 months filing pattern (this company)
- Total filings
- 36 filings
- Same category
- 19 filings
- Previous same-category filing
- 7/24/2026
- Corrections / withdrawals
- 0 filings
Filing source / License
The original PDF/HTML of this filing is provided by FSS DART. MarketBubbles displays only metadata (title, receipt number, type, reporter) and a rule-based summary; we do not mirror the original PDF body (per FSS ToS).